TYME - Tyme Technologies reverses gains after the sharp rise early this week

G0d4ather/iStock via Getty Images Tyme Technologies ([[TYME]] -9.6%) surged over a quarter of value on Monday on the back of a patent win related to its metabolomic technology platform. However, today, the shares are on a downward trend for the second straight session since then to continue the underperformance seen recently, as indicated in the graph. Here is a stock that faced deletion from the Russell 3000 Index on June 28 after falling over 24% over the past six months. Seeking Alpha contributor Biologics who is bullish on Tyme, highlights the potential of the company’s platform technology, which is designed to develop cancer metabolism-based therapies ((CMBTs)). “We won’t know if Tyme is “for real” until we see data from the company’s first pivotal trial for SM-88 in third-line pancreatic cancer,” the contributor wrote. However, in June, the company said it had decided to stop the trial following a strategic review.

For further details see:

Tyme Technologies reverses gains after the sharp rise early this week